GSK plc (NYSE:GSK) Shares Bought by Cypress Wealth Services LLC

Cypress Wealth Services LLC lifted its stake in shares of GSK plc (NYSE:GSK) by 23.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 11,966 shares of the pharmaceutical company’s stock after purchasing an additional 2,301 shares during the quarter. Cypress Wealth Services LLC’s holdings in GSK were worth $405,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in GSK. Eastern Bank purchased a new position in GSK in the third quarter valued at about $26,000. ST Germain D J Co. Inc. increased its stake in GSK by 195.5% in the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares in the last quarter. Sunbelt Securities Inc. boosted its position in GSK by 73.8% during the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 302 shares in the last quarter. Concord Wealth Partners grew its holdings in GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares during the last quarter. Finally, Fortitude Family Office LLC purchased a new position in shares of GSK in the third quarter valued at $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Price Performance

GSK stock opened at $33.50 on Friday. The stock has a market capitalization of $69.42 billion, a price-to-earnings ratio of 21.75, a price-to-earnings-growth ratio of 1.44 and a beta of 0.63. The stock’s fifty day simple moving average is $34.14 and its 200-day simple moving average is $38.04. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. This is a positive change from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.69%. The ex-dividend date of this dividend was Friday, November 15th. GSK’s dividend payout ratio is presently 96.10%.

Analysts Set New Price Targets

GSK has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and lowered their target price for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Finally, StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Monday. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.